EyePoint (EYPT) Other Non-Current Assets (2011 - 2026)
EyePoint (EYPT) posted Other Non-Current Assets of $9.3 million for Q1 2026, up 6102.67% sequentially from $150000.0 in Q4 2025, and up 6102.67% YoY from $150000.0 in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Other Non-Current Assets (2011 - 2026) Analysis & Trends
EyePoint has reported Other Non-Current Assets for 16 years, with the latest figure at $9.3 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 6102.67% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 6102.67% YoY) and the FY2025 annual result came in at $150000.0, down 97.43% from the prior year.
- Other Non-Current Assets grew to $9.3 million in Q1 2026 per EYPT's latest filing, from $150000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $9.3 million in Q1 2026 and troughed at $150000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $150000.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets plunged 97.43% in 2025, then soared 6102.67% in 2026.
- Over 5 years, Other Non-Current Assets stood at $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023, then soared by 3788.0% to $5.8 million in 2024, then slumped by 97.43% to $150000.0 in 2025, then jumped by 6102.67% to $9.3 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $9.3 million, $150000.0, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 9.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.37 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | 5.95 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | 5.90 Mn |
| Mar 31, 2025 | 5.88 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Sep 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 150,000.00 |
| Dec 31, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 150,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 150,000.00 |
| Sep 30, 2021 | 150,000.00 |